Company intelligence / Profile preview

Pluri’Ailes

Ownership: Private
Development stage: Commercial

Overview

Pluri (formerly Pluristem Therapeutics) is a global biotechnology and cell therapy company focused on regenerative medicine, food-tech, and agtech. They utilize a proprietary 3D cell expansion system for large-scale production of placental-derived adherent stromal cells and are developing an allogeneic MAIT cell therapy platform. Their therapeutic pipeline addresses indications such as muscle injuries, respiratory distress, peripheral artery disease, and hematopoietic complications.

Therapeutic areas: PulmonologyOncologyHematologyOtherCardiovascular
Modalities: Cell therapyInduced pluripotent stem cell derived therapy (placental-derived)Allogeneic MAIT cell therapy platformBiologic (cell-based products)Small molecule (for some agtech/food-tech applications)
Industry: Biotech

Partnerships

Immunotherapy collaborations

Beyond the preview

Go deeper on Pluri’Ailes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pluri’Ailes.

Explore the full profile